Michael J. Morris
#164,339
Most Influential Person Now
Researcher
Michael J. Morris's AcademicInfluence.com Rankings
Michael J. Morrisengineering Degrees
Engineering
#7210
World Rank
#8574
Historical Rank
Electrical Engineering
#2228
World Rank
#2334
Historical Rank
Michael J. Morriscomputer-science Degrees
Computer Science
#9722
World Rank
#10199
Historical Rank
Computational Linguistics
#2390
World Rank
#2413
Historical Rank
Machine Learning
#4333
World Rank
#4382
Historical Rank
Artificial Intelligence
#4686
World Rank
#4748
Historical Rank
Download Badge
Engineering Computer Science
Michael J. Morris's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Michael J. Morris Influential?
(Suggest an Edit or Addition)Michael J. Morris's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008) (2023)
- Organoid Cultures Derived from Patients with Advanced Prostate Cancer (2014) (1074)
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study (2010) (1004)
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. (2017) (539)
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. (2021) (478)
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. (2018) (452)
- Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. (2012) (431)
- Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. (2010) (413)
- Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. (2014) (391)
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade (2019) (364)
- Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. (2017) (309)
- Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer (2013) (305)
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. (2016) (281)
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer (2007) (274)
- Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer (2010) (269)
- Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer (2004) (268)
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. (2020) (260)
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update (2018) (258)
- Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. (2013) (234)
- Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). (2014) (210)
- Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer (2009) (208)
- End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. (2011) (208)
- Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. (2004) (201)
- Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. (2002) (198)
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. (2013) (197)
- Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. (2002) (170)
- HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. (2001) (166)
- A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. (2012) (163)
- Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer (2013) (155)
- A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. (2010) (155)
- Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. (2012) (151)
- HER‐2 profiling and targeting in prostate carcinoma (2002) (140)
- Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial (2018) (138)
- Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer* (2008) (137)
- Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards (2005) (136)
- Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer (2010) (126)
- A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (123)
- Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy (2005) (123)
- 11C-acetate PET imaging in prostate cancer (2007) (121)
- Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer (2005) (118)
- When progressive disease does not mean treatment failure: reconsidering the criteria for progression. (2012) (117)
- Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. (2015) (112)
- Pharmacokinetic Assessment of the Uptake of 16β-18F-Fluoro-5α-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET (2010) (110)
- 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer (2014) (108)
- Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. (2004) (108)
- Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. (2007) (99)
- First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake (2016) (93)
- Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients (2021) (91)
- Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study (2021) (90)
- α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1 (2018) (90)
- A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY) (2021) (89)
- Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. (2009) (89)
- Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases (2007) (87)
- Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. (2014) (85)
- Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy (2008) (83)
- Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. (2009) (83)
- Validation and clinical utility of prostate cancer biomarkers (2013) (82)
- Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. (2020) (82)
- Targeting the androgen receptor in prostate and breast cancer: several new agents in development. (2015) (79)
- Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial (2018) (76)
- Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer (2020) (76)
- PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. (2004) (75)
- Androgen deprivation and thromboembolic events in men with prostate cancer (2012) (75)
- Imaging therapeutic response in human bone marrow using rapid whole‐body MRI (2004) (73)
- Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer (2017) (72)
- Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors (2007) (70)
- Methylphenidate for fatigue in ambulatory men with prostate cancer (2010) (70)
- Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. (2019) (69)
- Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. (2020) (67)
- Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. (2003) (66)
- A polyvalent vaccine for high-risk prostate patients: “are more antigens better?” (2007) (65)
- Current perspectives on bone metastases in castrate-resistant prostate cancer (2018) (63)
- Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy (2017) (62)
- Brain Metastases from Prostate Cancer: An 11‐Year Analysis in the MRI Era with Emphasis on Imaging Characteristics, Incidence, and Prognosis (2014) (62)
- Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. (2018) (61)
- Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials (2006) (61)
- Repeatability of Quantitative 18F-NaF PET: A Multicenter Study (2016) (60)
- Radium-223 mechanism of action: implications for use in treatment combinations (2019) (58)
- Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. (2020) (58)
- Novel strategies and therapeutics for the treatment of prostate carcinoma (2000) (58)
- Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. (2013) (57)
- Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors (2015) (57)
- Radiation Safety Considerations for the Use of 223RaCl2 DE in Men with Castration-resistant Prostate Cancer (2014) (55)
- α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 2 (2018) (53)
- A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. (2013) (53)
- Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics (2019) (49)
- Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). (2014) (47)
- Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT (2011) (47)
- Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone. (2017) (46)
- Computer-aided quantitative bone scan assessment of prostate cancer treatment response (2012) (45)
- Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer (2016) (45)
- Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2018) (44)
- Developing imaging strategies for castration resistant prostate cancer (2011) (42)
- Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy (2016) (42)
- A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. (2017) (42)
- Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy (2008) (41)
- Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide (2016) (41)
- PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN (2019) (40)
- Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial (2018) (40)
- Therapeutic Implications of Germline Testing in Patients With Advanced Cancers (2021) (40)
- Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). (2021) (40)
- A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. (2007) (40)
- Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. (2019) (38)
- Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer (2010) (38)
- High‐dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma (2004) (37)
- A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. (2012) (37)
- Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). (2019) (37)
- Clinical approaches to osseous metastases in prostate cancer. (2003) (36)
- Re: Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. (2000) (36)
- Expression of prostate-specific membrane antigen in renal cortical tumors (2008) (36)
- Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. (2022) (35)
- VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). (2019) (35)
- Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody (2019) (35)
- Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma (2003) (35)
- Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC) (2008) (34)
- CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. (2019) (34)
- Androgen‐deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? (2018) (33)
- Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial (2019) (33)
- Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. (2020) (32)
- Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? (2013) (32)
- (11)C-acetate PET imaging in prostate cancer. (2007) (32)
- A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors (2012) (32)
- Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. (2016) (32)
- Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance) (2015) (31)
- Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working group (2018) (31)
- The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). (2015) (30)
- Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae in Prostate Cancer (2012) (30)
- Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. (2008) (30)
- Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. (2020) (29)
- Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study. (2013) (29)
- Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging (2021) (28)
- Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling (2022) (28)
- Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications (2015) (27)
- Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. (2009) (27)
- Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. (2019) (27)
- Safety and Biologic Activity of Intravenous BCL-2 Antisense Oligonucleotide (G3139) and Taxane Chemotherapy in Patients With Advanced Cancer (2005) (27)
- Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer (2006) (26)
- Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. (2013) (26)
- Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers (2014) (25)
- Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. (2000) (25)
- Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. (2015) (25)
- A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition (2016) (24)
- Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial (2019) (24)
- Simultaneous quantitation of abiraterone, enzalutamide, N‐desmethyl enzalutamide, and bicalutamide in human plasma by LC–MS/MS (2017) (24)
- Harnessing Naturally Occurring Tumor Immunity: A Clinical Vaccine Trial in Prostate Cancer (2010) (23)
- Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR). (2020) (23)
- Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19 (2021) (23)
- Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study (2020) (23)
- Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial (2012) (22)
- Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer (2021) (22)
- Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time. (2018) (22)
- Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. (2019) (21)
- Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP). (2015) (21)
- PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). (2019) (21)
- Repetitively dosed docetaxel and 153samarium‐EDTMP as an antitumor strategy for metastatic castration‐resistant prostate cancer (2013) (20)
- The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer (2013) (20)
- Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. (2020) (20)
- Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting. (2015) (20)
- Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone (2019) (19)
- High‐dose chemotherapy as primary treatment for poor‐risk germ‐cell tumors: The Memorial Sloan‐Kettering experience (1988–1999) (1999) (19)
- Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial. (2015) (19)
- Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. (2016) (19)
- Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases. (2016) (19)
- CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial (2016) (19)
- Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study (2018) (18)
- Results from the OSPREY trial: A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients with PRostate Cancer - Examination of Diagnostic AccuracY (2019) (18)
- Assessing outcomes in prostate cancer clinical trials (2008) (18)
- 2530 Baseline characteristics, number of radium-223 (Ra-223) injections, and overall survival (OS) in US Expanded Access Program (EAP) and ALSYMPCA (2015) (18)
- Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance) (2021) (18)
- Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study. (2012) (18)
- Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. (2002) (18)
- A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). (2014) (17)
- Inherited TP53 Variants and Risk of Prostate Cancer. (2021) (17)
- The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. (2014) (16)
- Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer (2008) (16)
- Ra-223 experience in pretreated patients: EAP setting. (2015) (16)
- Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. (2002) (15)
- Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor–Axis Imaging (2016) (15)
- A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. (2020) (15)
- Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting (2020) (15)
- Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors (2021) (15)
- Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer (2016) (15)
- Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer (2018) (15)
- Microsatellite instability in prostate cancer and response to immune checkpoint blockade. (2018) (14)
- A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance) (2015) (14)
- Integrative Clinical Genomics of Advanced Prostate Cancer Graphical (2015) (14)
- Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation. (2019) (13)
- 11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series (2019) (13)
- Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: ASCO Clinical Practice Guideline Summary. (2018) (13)
- C-acetate PET imaging in prostate cancer (2007) (13)
- VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). (2019) (12)
- Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer. (2020) (12)
- A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer (2021) (12)
- Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study. (2013) (12)
- Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer (2019) (12)
- Effect of radium-223 dichloride (Ra-223) on pain from US EAP. (2015) (12)
- Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials (2019) (12)
- CD38 in Advanced Prostate Cancers (2021) (12)
- Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer (2016) (12)
- Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer. (2016) (12)
- LBA38Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) (2017) (11)
- Targeting bone physiology for the treatment of metastatic prostate cancer. (2013) (11)
- Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors (2020) (11)
- The Role of Theranostics in Prostate Cancer. (2021) (11)
- Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). (2006) (11)
- Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). (2012) (11)
- CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC). (2019) (10)
- Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance) (2020) (10)
- Fully automated synthesis of [(18) F]fluoro-dihydrotestosterone ([(18) F]FDHT) using the FlexLab module. (2016) (10)
- Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy. (2015) (10)
- Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC). (2011) (10)
- The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer (2007) (10)
- Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer. (2020) (10)
- Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series (2018) (10)
- Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3 (2022) (9)
- Phase I study of docetaxel and 153Sm repetitively administered for castrate metastatic prostate cancer (CMPC) (2007) (9)
- BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer (2001) (8)
- Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer (2020) (8)
- Long–Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer (2017) (8)
- Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy (2020) (8)
- Phase 2 trial of 177Lutetium (177Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (177Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). (2008) (8)
- Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC) (2019) (8)
- A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT. (2020) (8)
- Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): A phase I/IIa clinical trial. (2017) (8)
- Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study (2021) (8)
- A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer (2019) (8)
- Phase I/II study of docetaxel and 153Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort. (2009) (8)
- Association of Radiographic Progression-Free Survival (RPFS) Adapted from Prostate Cancer Working Group 2 (PCWG2) Consensus Criteria (APCWG2) with Overall Survival (OS) in Patients (PTS) with Metastatic Castration-Resistant Prostate Cancer (MCRPC): Results from COU-AA-302 (2012) (8)
- Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study. (2012) (8)
- Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen. (2005) (8)
- A phase II study combining ipilimumab and degarelix with or without radical prostatectomy (RP) in men with newly diagnosed metastatic noncastration prostate cancer (mNCPC) or biochemically recurrent (BR) NCPC. (2017) (8)
- Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC). (2019) (7)
- Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer (2013) (7)
- Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC). (2018) (7)
- Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer (2019) (7)
- Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study. (2011) (7)
- Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. (2018) (7)
- Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer (2018) (7)
- PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer. (2022) (7)
- The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload. (2011) (7)
- Seek and Find: Current Prospective Evidence for Prostate-specific Membrane Antigen Imaging to Detect Recurrent Prostate Cancer. (2021) (7)
- 765PDSAFETY OF RADIUM-223 DICHLORIDE (RA) WITH DOCETAXEL (D) IN PATIENTS (PTS) WITH BONE METASTASES (METS) FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A PHASE 1/2A CLINICAL TRIAL. (2014) (7)
- The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD (2018) (7)
- Phase II Study of Lutetium-177 – Labeled Anti-Prostate-Speci fi c Membrane Antigen Monoclonal Antibody J 591 for Metastatic Castration-Resistant Prostate Cancer (2013) (7)
- Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial. (2018) (7)
- A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC). (2011) (7)
- Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD) (2021) (6)
- Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203). (2018) (6)
- Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial. (2020) (6)
- A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). (2019) (6)
- Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). (2021) (6)
- Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer (2022) (6)
- Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (2018) (6)
- Failure of ELM-PC 5: an ineffective drug or an unfit end point? (2015) (6)
- Phase II study of bortezomib for castrate metastatic prostate cancer (PC) (2005) (6)
- Diversity of biology in castrate resistant prostate cancer (2009) (6)
- A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research (2020) (6)
- Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium‐223 (2017) (6)
- A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration‐resistant prostate cancer (2018) (6)
- A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY). (2018) (6)
- A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial. (2016) (5)
- Reproducibility and clinical correlations of post-treatment changes on CT of prostate cancer bone metastases treated with chemotherapy. (2012) (5)
- Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions. (2007) (5)
- 89Zr J591 immunoPET imaging in patients with prostate cancer (2013) (5)
- Imaging metastatic castration-resistant prostate cancer patients with 89Zr-DFO-MSTP2109A anti-STEAP1 antibody (2019) (5)
- CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC). (2021) (5)
- Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in hormone refractory prostate cancer after failure of taxane-based therapy (2005) (5)
- Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes. (2019) (5)
- A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases. (2012) (5)
- Abstract 2069: Initial PET imaging and pharmacokinetic results from a Phase I/II study of Zr-89-labeled anti-STEAP1 antibody in metastatic castrate-resistant prostate cancer (mCRPC) patients (2014) (5)
- HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial. (2010) (5)
- Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center. (2003) (5)
- Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. (2016) (5)
- Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT. (2017) (5)
- The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer. (2021) (5)
- What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (2022) (4)
- A phase I/II trial of RAD 001 with gefitinib in patients with castrate metastatic prostate cancer and glioblastoma multiforme. (2006) (4)
- First in Human 89Zr-Df-IAB2M anti-prostate specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer. (2015) (4)
- Targeting reciprocal feedback inhibition: Apalutamide and everolimus in patients with metastatic castration-resistant prostate cancer (mCRPC). (2017) (4)
- Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy. (2010) (4)
- Docetaxel for Early Prostate Cancer: What Have We Learned? (2020) (4)
- Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. (2014) (4)
- 576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (2021) (4)
- LBA19 THE MEN’S EATING AND LIVING (MEAL) STUDY (CALGB 70807 [ALLIANCE]): A RANDOMIZED CLINICAL TRIAL OF A DIET INTERVENTION IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER (2018) (4)
- Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? (2022) (4)
- Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer (CRPC). (2010) (4)
- PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer. (2022) (4)
- Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC). (2017) (4)
- A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naïve patients with progressive metastatic castration resistant prostate cancer (mCRPC). (2016) (4)
- LBA-12 CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER (2019) (4)
- MP24-01 RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN PATIENTS WITH MICROSATELLITE INSTABLE AND HIGH TUMOR MUTATIONAL BURDEN PROSTATE CANCER (2021) (3)
- Genitourinary tumors, prostate (2012) (3)
- Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy. (2012) (3)
- Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer. (2022) (3)
- Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa). (2019) (3)
- Zr-J 591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (3)
- PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs. (2018) (3)
- Translating Prostate Cancer Working Group 2 (PCWG2) progression criteria into a quantitative response biomarker in metastatic castration-resistant prostate cancer (mCRPC). (2017) (3)
- MO-AB-BRA-05: [18F]NaF PET/CT Imaging Biomarkers in Metastatic Prostate Cancer. (2016) (3)
- Risk assessment for severe hypocalcemia requiring hospitalization with denosumab. (2013) (3)
- Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. (2021) (3)
- A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19). (2018) (3)
- Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone. (2010) (3)
- Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease (2016) (3)
- STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC). (2015) (3)
- The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer. (2022) (2)
- Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) (2007) (2)
- A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa). (2016) (2)
- Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib. (2013) (2)
- A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. (2021) (2)
- Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC): Study update (2016) (2)
- 1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial (2022) (2)
- Phase I trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC). (2012) (2)
- ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203). (2018) (2)
- LBA63 PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19) (2022) (2)
- Next-generation sequencing (NGS) of tissue and cell free DNA (cfDNA) to identify somatic and germline alterations in advanced prostate cancer. (2017) (2)
- 648TiP PSMAfore: A phase III study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC (2021) (2)
- Phase 2 trial of 177Lutetium (177Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (177Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) (2006) (2)
- Translating prostate cancer working group (PCWG) criteria into a quantitative progression biomarker in metastatic castration resistant prostate cancer (mCRPC). (2017) (2)
- A phase II trial of rapid androgen cycling and docetaxel (Doc) in prostate cancer patients with a rising prostate-specific antigen (PSA) in the noncastrate state (2007) (2)
- 793PDPhase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC) (2017) (2)
- Phase I dose-escalation study of AGS-PSCA, an anti-PSCA human antibody, in castration-resistant prostate cancer (2007) (2)
- The men’s cycle plus docetaxel (Doc) in prostate cancer patients with rising PSAs in the non-castrate state (2005) (2)
- Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod. (2013) (2)
- Comparison of PSA, FDG-PET, and Prostate Cancer Working Group 2 (PCWG2) criteria to interpret apparent progression on first post-treatment bone scan. (2012) (2)
- Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591. (2015) (2)
- Multilineage plasticity in prostate cancer through expansion of stem–like luminal epithelial cells with elevated inflammatory signaling (2021) (2)
- Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer. (2013) (2)
- A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. (2021) (2)
- Diagnostic performance of 18F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC). (2019) (2)
- Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons. (2019) (2)
- MP82-04 PELVIC EXENTERATION IN PATIENTS WITH NON-METASTATIC, LOCALLY ADVANCED CASTRATION-RESISTANT PROSTATE CANCER (2015) (2)
- Phase I trial of exogenous testosterone (T) for the treatment of castrate metastatic prostate cancer (PC). (2004) (2)
- Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer. (2014) (2)
- Abstract A221: Results of preclinical and clinical phase I/II open‐label dose‐ranging trial with HE3235, a synthetic adrenal hormone, in castrate‐resistant prostate cancer (2009) (2)
- Genomic characterization of primary and metastatic prostate cancer (PC) using a targeted next-generation sequencing assay. (2015) (2)
- Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality (2021) (2)
- Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. (2019) (1)
- Characterization of findings on prostate cancer tumor sequencing that should prompt consideration for germline testing. (2021) (1)
- Hormonal induction followed by rapid hormonal cycling for prostate cancer (PC): the MEN's Cycle (2004) (1)
- CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC). (2018) (1)
- 647TiP PSMAddition: A phase III trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer (2021) (1)
- Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC). (2015) (1)
- A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). (2016) (1)
- Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). (2016) (1)
- An open-label phase Ib study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide. (2020) (1)
- PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. (2021) (1)
- 18F-16β-fluoro-5α-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC). (2012) (1)
- Initial analytic validation of automated bone scan measures for treatment response assessment in patients with metastatic castration-resistant prostate cancer (CRPC). (2011) (1)
- Androgens and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel (2020) (1)
- MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE) (2015) (1)
- Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer (2022) (1)
- A Phase I/II Study for Analytic Validation of Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (1)
- From Concept to Regulatory Drug Approval: Lessons for Theranostics (2022) (1)
- Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC). (2013) (1)
- Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer. (2019) (1)
- Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). (2022) (1)
- A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results. (2014) (1)
- Reply to B. Rini et al and S. Buti et al. (2017) (1)
- PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL (2020) (1)
- Minibody imaging of prostate-specific membrane antigen (PSMA): From concept to clinic. (2014) (1)
- Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC). (2022) (1)
- Clinical versus radiographic progression and overall survival for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from COU-AA-302. (2017) (1)
- Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer (2020) (1)
- Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL. (2016) (1)
- Automated tumor detection on bone scans for treatment response assessment. (2011) (1)
- Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy (2021) (1)
- 1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC) (2022) (1)
- Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. (2022) (1)
- Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel (2020) (1)
- Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: A sub-study of the VISION trial. (2020) (1)
- Evaluating 18F-16β-fluoro-5α-dihydrotestosterone (FDHT) and FDG PET as prognostic biomarkers for patients (pts) treated with abiraterone acetate (AA). (2014) (1)
- Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers. (2013) (1)
- Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. (2022) (1)
- Fluorodeoxyglucose Positron EmissionTomography as an Outcome Measure for CastrateMetastatic Prostate CancerTreatedwith Antimicrotubule Chemotherapy (2005) (1)
- Automated bone scan index as a quantitative imaging biomarker indicative of efficacy to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC). (2016) (1)
- Decline in serum androgens and survival in metastatic castration resistant prostate cancer (MCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (alliance) (2018) (1)
- Pathologic correlation of 18F-16{beta}-fluoro-5{alpha}-dihydrotestosterone (FDHT) and FDG PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2014) (1)
- Prevention of hip fractures in older men receiving androgen deprivation therapy for prostate cancer: A cost-effectiveness analysis. (2009) (1)
- Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance). (2017) (1)
- Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study (2006) (1)
- Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer (2022) (1)
- 89Zr-IAB2M minibody imaging in patients with prostate cancer: Biodistribution, kinetics, lesion uptake and organ dosimetry (2014) (1)
- 79 POSTER Correlative results of in-vivo monitoring of platelet-derived growth factor receptor (PDGFR) activation status in a randomized placebocontrolled trial of docetaxel +/− imatinib in castration-resistant prostate cancer (CRPC) and bone metastases (BM) (2006) (0)
- Correlation between Imaging-based Intermediate Endpoints and Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials using the Prostate Cancer Clinical Trials Working Group (PCWG2) criteria in 16,511 patients (2021) (0)
- Reply to Tomasz Drewa and Piotr Chlosta’s Letter to the Editor re: Michael J. Morris, Daisy Huang, William K. Kelly, et al. Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate. Eur Urol 2009;56:237–44 (2010) (0)
- Evaluation of a multimodal strategy to accelerate drug evaluations in early-stage metastatic prostate cancer. (2017) (0)
- PD44-01 WHEN SHOULD PROSTATE CANCER TUMOR SEQUENCING PROMPT CONSIDERATION FOR GERMLINE TESTING? (2021) (0)
- The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer (2022) (0)
- Phase I Trial of Asg-5me in Metastatic Castration Resistant Prostate Cancer (CRPC) (2012) (0)
- Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer. (2021) (0)
- PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials. (2018) (0)
- Tumor testing in men with prostate cancer to predict for germline DNA-damage repair mutations. (2019) (0)
- A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA. (2019) (0)
- Pretherapeutic first-in-human targeting trial of anti-hK2 antibody h11B6: A potential molecular vector for alpha-particle radioimmunotherapy. (2021) (0)
- Imaging and pharmacokinetics with escalating doses of Radium-223 chloride in bone-metastatic castration resistant prostate cancer (CRPC) during a phase I study (2010) (0)
- Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19). (2023) (0)
- PD60-10 A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF 18F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER – EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY) (2019) (0)
- Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score. (2022) (0)
- Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer (2020) (0)
- Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). (2023) (0)
- Automated analysis of FDG-PET/CT imaging to monitor heterogeneous disease response in metastatic castration-resistant prostate cancer. (2023) (0)
- Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). (2023) (0)
- Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE). (2014) (0)
- Decision aids for localized prostate cancer: Initial outcomes from NCI Community Oncology Research Program Alliance Research Base Cancer Care Delivery Research (CCDR) Protocol - A191402CD - A Cluster-Randomized Trial. (2020) (0)
- Abstract LB-203: Phase I/II study of the androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (2008) (0)
- Fluorodeoxyglucose (FDG) positron emission tomography (PET) as an indicator of disease progression for patients with castration-resistant metastatic prostate cancer (CRMPC). (2011) (0)
- Initial study of bone scan tumor area for early surrogate outcome assessment in patients with metastatic castration-resistant prostate cancer. (2011) (0)
- Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022. (2023) (0)
- Pelvic exenteration in patients with nonmetastatic, locally advanced castration-resistant prostate cancer. (2014) (0)
- PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. (2021) (0)
- Michael J. Morris, MD on the Impact of PyL-PET/CT Scans on the Clinical Management of Patients With Prostate Cancer (2020) (0)
- PD03-12 LONG-TERM DECISIONAL REGRET FOR MINORITY MEN DIAGNOSED WITH PROSTATE CANCER: RESULTS FROM A MULTI-CENTERED RANDOMIZED CLINICAL TRIAL OF DECISION AID (2021) (0)
- LBA02-12 A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL (2020) (0)
- Targeting osseous metastases: rationale and development of radioimmunotherapy for prostate cancer (2005) (0)
- The timing of molecular imaging in prostate cancer. (2018) (0)
- Abstract IA22: Molecular Imaging of androgen receptor signalling in CRPC (2012) (0)
- MP11-11 CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL (2021) (0)
- Fluorodeoxyglucose (FDG) PET as an outcome measure for metastatic prostate cancer. (2010) (0)
- CHAARTED: ADT Plus Docetaxel in Prostate Cancer (2014) (0)
- Abstract CT031: A phase Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer (mCRPC) (2017) (0)
- Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). (2021) (0)
- Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. (2022) (0)
- Abstract LB-070: Next generation sequencing of prostate cancer reveals germline and somatic alterations detected at diagnosis and at metastasis that may impact clinical decision making (2016) (0)
- Abstract P041: Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer (2021) (0)
- Prostate Cancer: Systemic therapy (2008) (0)
- Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy (2019) (0)
- Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE) (2014) (0)
- A case report of putative autoimmunity to prostate cancer after immune-mediated rejection of melanoma through a shared tumor antigen. (2012) (0)
- The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer (2014) (0)
- Targeting osseous metastases: Rationale and development of radioimmunotherapy for prostate cancer (2004) (0)
- Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC) (2019) (0)
- Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply. (2019) (0)
- Magnetic resonance imaging of the bone marrow (MRBM) as an outcome measure for patients with metastatic prostate cancer. (2006) (0)
- Wholebody Clearance Of Three 89Zr Labeled Antibodies:Differences between PET based and Whole Body Probe Based Clearance (2015) (0)
- The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload. (2011) (0)
- Effect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer. (2023) (0)
- Title : A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with 2 Metastatic Castration-Resistant Prostate Cancer 3 (2021) (0)
- 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer (2004) (0)
- Use of bone modifying agents for metastatic castrate-resistant prostate cancer. (2022) (0)
- Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with BoneMetastases (2007) (0)
- Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score. (2022) (0)
- EVALUATION OF A MULTIMODAL STRATEGY TO ACCELERATE DRUG EVALUATIONS IN EARLY STAGE METASTATIC PROSTATE CANCER: PD24‐11 (2017) (0)
- Phase I trial results of PCK3145 in patients (pts) with castrate metastatic prostate cancer (PC)-The US experience. (2016) (0)
- Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. (2023) (0)
- Reply to K. Lu. (2015) (0)
- Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. (2022) (0)
- Resource Integrative Clinical Genomics of Advanced Prostate Cancer (2016) (0)
- PCK3145, a novel multitargeted signalling agent for the treatment of castrate metastatic prostate cancer (CMPC) (2007) (0)
- Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients (2023) (0)
- Phase 0 study to assess [111In]-DOTA-h11B6 to target human kallikrein-2 (hk2) in men with metastatic castration-resistant prostate cancer. (2020) (0)
- Tc-MDP Bone Scan in Progressing Metastatic Prostate Cancer (2010) (0)
- Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. (2023) (0)
- Clinical characteristics and outcomes of patients with prostate cancer and parenchymal brain metastases (PBM). (2014) (0)
- A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). (2014) (0)
- Bone Directed Approaches and Imaging Biomarkers (2014) (0)
- Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance) (2016) (0)
- Clinical State of the Rising PSA Value after Definitive Local Therapy (2012) (0)
- Comparison of PSA, FDG-PET, and Prostate Cancer Working Group 2 (PCWG2) criteria to interpret apparent progression on first post-treatment bone scan. (2012) (0)
- A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801). (2021) (0)
- Abstract 1308:CDK12alterations define a distinct molecular subtype of prostate cancers with unique genomic and clinical characteristics (2020) (0)
- MP87-12 RADIUM-223 DICHLORIDE IN EXPANDED-ACCESS SETTING IN THE UNITED STATES: OVERALL AND CONCURRENT EXPERIENCE WITH ABIRATERONE OR ENZALUTAMIDE (2015) (0)
- Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials (2019) (0)
- P106 Results from a Phase I study of enzalutamide in combination with docetaxel in men with prostate cancer (2013) (0)
- A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. (0)
- Barriers to guideline-concordant use of bone modifying agents for prostate cancer. (2023) (0)
- Hormonal induction followed by rapid hormonal cycling for prostate cancer (PC): the MEN's Cycle. (2004) (0)
- Imaging , Diagnosis , Prognosis Prognostic Value of Baseline [ 18 F ] Fluorodeoxyglucose Positron Emission Tomography and 99 mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer (2010) (0)
- Cancer Therapy : Clinical Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer (2009) (0)
- Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC). (2019) (0)
- Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer. (2023) (0)
- Current perspectives on bone metastases in castrate-resistant prostate cancer (2018) (0)
- Lineage plasticity is a well–established mechanism of resistance to targeted therapies in lung and prostate cancer, where tumors transition from adenocarcinoma to small–cell or neuroendocrine carcinoma. Through single–cell analysis of a cohort of heavily–treated castration–resistant human prostate c (2021) (0)
- External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. (2023) (0)
- A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes. (2023) (0)
- Looking at the Future of Prostate Cancer Treatment (2023) (0)
- 2006 Conference on Innovations and Challenges in Prostate Cancer (2007) (0)
- A model assessing how variable timing of outcome assessments impacts progression-free survival (PFS) (2007) (0)
- Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC). (2020) (0)
- [18F]NaF PET/CT imaging biomarkers of progression-free survival in metastatic prostate cancer. (2016) (0)
- Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. (2007) (0)
- Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer (2018) (0)
- Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC). (2014) (0)
- Automated synthesis of 16β-[18F]fluoro-5α-dihydrotestosterone using the FlexLab radiosynthesizer (2015) (0)
- Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer. (2021) (0)
- Editorial commentary 11 C-acetate PET imaging in prostate cancer (2007) (0)
- Targeted radioimmunotherapy (RIT) with 177Lutetium labeled J591, anti-prostate-specific membrane antigen (PSMA) monoclonal antibody: Initial results of a phase 2 trial in patients with metastatic androgen-independent prostate cancer (AIPC) (2007) (0)
- Phase I dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC). (2010) (0)
- Analytical Validation of Automated Bone Scan Index (BSI) as an Imaging Biomarker in Patients with Metastatic Prostate Cancer (mPC) (2015) (0)
- Predictive biomarkers of overall survival in patients with renal cell carcinoma treated with interferon alpha +/- bevacizumab: Results from CALGB 90206 (Alliance). (2021) (0)
- A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC). (2017) (0)
- PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. (2023) (0)
- Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11] (2022) (0)
- Advances in Prostate Cancer Imaging (2022) (0)
- Abstract 979: Bcl-2 inhibitor enhances anti-androgen therapy induced regression of castration sensitive prostate cancer (2021) (0)
- Impact of anatomic location of bone metastases on prognosis in mCRPC (2020) (0)
- 672 Prior and concurrent use of abiraterone and enzalutamide with radium-223 dichloride (Ra-223) in US expanded access setting (EAP) (2015) (0)
- Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer. (2023) (0)
- Pathologic correlation of 89Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer. (2015) (0)
- Phase I Evaluation ofJ 591 as a Vascular Targeting Agent in Progressive SolidTumors (2007) (0)
- Abstract 2200: Multilineage plasticity in prostate cancer through expansion of stem-like luminal epithelial cells with elevated inflammatory signaling (2022) (0)
- Molecular Imaging, Clinical Trial Design, and the Development of Emerging Therapies for Metastatic Prostate Cancer (2006) (0)
- PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
- LBA02-11 UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19) (2023) (0)
- Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B). (2018) (0)
- Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance). (2021) (0)
- 343 ANDROGEN DEPRIVATION AND THROMBOEMBOLIC EVENTS IN MEN WITH PROSTATE CANCER (2011) (0)
- Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC). (2023) (0)
- Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy. (2017) (0)
- Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance). (2017) (0)
- Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series (2018) (0)
- Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy. (2012) (0)
- The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401). (2012) (0)
- 1397P Phase I results of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael J. Morris?
Michael J. Morris is affiliated with the following schools:
